Last Updated 16 December 2015
Schizophrenia is an often disabling psychiatric disease whose core treatment consists of years up to a lifetime of treatment with antipsychotics (older typical antipsychotics or newer atypical antipsychotics). With at least nine different atypical antipsychotic molecules available in most major markets under study (United States, France, Germany, Italy, Spain, United Kingdom, Japan), as well as typical antipsychotic options, new entrants must differentiate themselves to garner a foothold in the market. Sales of premium-priced emerging therapies and the continued uptake of long-acting depot formulations of atypical antipsychotics will not overcome sales of top-selling antipsychotics lost to generic erosion during our 2014-2024 study period. The schizophrenia market will grow from nearly $6.5 billion in 2014 to over $6.6 billion in 2015 and remain relatively stable at approximately $6.5 billion through 2018, due to the launches and continued uptake of newer-to-market agents; however, in the latter half of the forecast period, major-market sales will decline to $6.0 billion in 2021 and remain at that level through 2024, owing to the generic erosion of key players across the major markets. Emerging therapies in development include two new atypical antipsychotics, Otsuka/Lundbeck’s brexpiprazole (Rexulti) and Allergan (formerly Forest Laboratories)/Gedeon Richter/Mitsubishi Tanabe Pharma’s cariprazine (Vraylar), and two new depot formulations of current antipsychotics, Janssen’s paliperidone palmitate (three-month formulation; Invega Trinza) and Alkermes’s aripiprazole lauroxil (Aristada).